Impaired Renal Function Clinical Trial
Official title:
Effects of Obesity Surgery on Renal Function
Increasing risk of impaired renal function as a result of obesity is well known. Early data has postulated that weight loss might improve kidney function, but the evidence is rather limited due to the difficulties in measuring glomerular filtration rate(GFR) after weight loss. Cystatin C, GFR measurement using Cockcroft-Gault (CCG) and Modification of Diet in Renal Disease (MDRD) equations, have all yield conflicting results after weight loss surgery. The study aim to assess: 1. use of 51Cr-EDTA Clearance as the methodological gold standard in evaluating changes in renal function before and after weight loss surgery. 2. the reliability of using MDRD, CCG and Cystatin C in measuring GFR after weight loss surgery 3. the differences in alterations in renal function dependent on the surgical procedures( gastric bypass, gastric band, sleeve gastrectomy). 4. the use of urine albumin/creatinine ratio in detecting alterations in microalbuminuria.
This is a prospective study on obese human subjects undergoing bariatric surgery. Forty-five patients due to undergo gastric bypass (n=15), gastric banding (n=15), and gastric sleeve surgery (n=15) will be recruited. Subjects will be screened prior to entry into the study with full history, examination, routine bloods (FBC, U+E, liver function tests, and glucose). 1. Blood samples and 24h urine specimens are taken at four time points: preoperatively as well 6 weeks, 6 and 12 months postoperatively. 2. The following methods of GFR assessment will be executed the same time point: measurement of serum creatinine concentration, calculation of the abbreviated and extended MDRD formulae, CCG, creatinine clearance, serum Cystatin C concentration and the 51Chromium-EDTA clearance. Inclusion criteria 1. Patients with a BMI of >35kg/m2 approved for obesity surgery based on the NICE criteria. 2. Patients with a GFR <60 mL/min/1.73 Exclusion criteria 1. Allergy to chromium ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04252430 -
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01716455 -
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
|
Phase 1 | |
| Completed |
NCT02431481 -
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
|
Phase 1 | |
| Completed |
NCT02087566 -
Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)
|
N/A | |
| Completed |
NCT04179630 -
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
|
Phase 1 | |
| Completed |
NCT00779922 -
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
|
Phase 2 | |
| Completed |
NCT00784381 -
Computer Prescribing System and Impaired Renal Function
|
Phase 3 | |
| Active, not recruiting |
NCT01760031 -
Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy
|
N/A | |
| Completed |
NCT03776539 -
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
|
Phase 1 | |
| Completed |
NCT01035320 -
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
|
Phase 4 | |
| Completed |
NCT00604357 -
CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
|
Phase 3 | |
| Completed |
NCT02965040 -
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
|
Phase 1 | |
| Completed |
NCT00981045 -
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
|
Phase 3 | |
| Completed |
NCT02467478 -
Linagliptin's Effect on CD34+ Stem Cells
|
Phase 4 | |
| Recruiting |
NCT04620590 -
An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function
|
Phase 4 |